**Comprehensive Medical Report**

**Patient Information**

* Age: 49
* Sex: Male
* Performance Status: ECOG 2

**Medical History**

* Muscle-invasive bladder cancer
* Prior treatments:
	+ Transurethral resection of the bladder tumor (TURBT)
	+ 6 cycles of cisplatin and gemcitabine chemotherapy
	+ 4 cycles of pembrolizumab immunotherapy
* Current disease status: Progressive disease despite standard treatments

**Symptoms and Side Effects**

* Fatigue
* Peripheral neuropathy (tingling in hands and feet)
* Joint pain
* Skin rash
* Mild anemia

**Current Medications**

* None

**Laboratory Results**

* Liver function tests (ALT, AST, bilirubin): Within normal ranges
* Kidney function (creatinine): Mild increase during chemotherapy, but no significant damage
* PD-L1 expression: High
* Molecular profiling (NGS): No actionable mutations, including FGFR3 or ERBB2

**Physical Examination**

* No significant findings

**Imaging Results**

* Recent imaging confirmed disease progression

**Clinical Trials Eligibility**

* Open to participating in all phases of clinical trials (I, II, III)
* Willing to consider trials with various treatment combinations, including immunotherapy, chemotherapy, and targeted therapies
* No known liver-related issues or abnormalities

**Potential Clinical Trials**

* NCT04856189 (Selinexor and Pembrolizumab combination trial)
* Other trials targeting muscle-invasive bladder cancer with similar treatment combinations or alternative approaches

**Special Considerations**

* Prior pembrolizumab treatment may impact eligibility for certain trials
* Mild anemia and peripheral neuropathy may require monitoring during future treatments
* Patient's ECOG score of 2 may impact eligibility for trials with specific performance status requirements

**Conclusion**

This patient is a 49-year-old male with muscle-invasive bladder cancer who has progressed despite standard treatments. He is open to participating in all phases of clinical trials and willing to consider various treatment combinations. His medical history, laboratory results, and imaging findings are provided to facilitate clinical trial eligibility evaluation.